Team
Christopher E. Mason,
Ph.D.
Dr Christopher Mason is a Professor of Genomics, Physiology, Biophysics, and Neuroscience at Weill Cornell Medicine and Director of the WorldQuant Initiative for Quantitative Prediction. He completed a dual B.S. in Genetics & Biochemistry at University of Wisconsin-Madison (2001), a Ph.D. in Genetics at Yale University (2006), Clinical Genetics Fellowship at Yale Medical School (2009), and was the Visiting Fellow of Genomics, Ethics, and Law at Yale Law School (2006-2009). His laboratory creates and deploys new technologies and algorithms for medicine, integrative omics, and cell/genome engineering, spanning >350 peer-reviewed papers, five patents, five diagnostics tests, 10 biotechnology companies, and 4 non-profits. Dr. Mason also holds affiliate faculty appointments at the New York Genome Center, Yale Law School, and the Consortium for Space Genetics at Harvard Medical School. He is the author of The Next 500 Years: Engineering Life to Reach New Worlds and The Age of Prediction.
Savi Glowe
Savi Glowe is the Co-Founder and CEO of BioAstra, a nonprofit advancing the future of healthcare on Earth through medical research and innovation in space. With over a decade of leadership at the intersection of healthcare, technology, and research operations, she brings deep expertise in digital health, clinical trial innovation, and strategic development.
Previously, Savi held senior roles at the Icahn School of Medicine at Mount Sinai, where she mobilized cross-disciplinary expertise in data science, genomics, and clinical care. She also served as Chief Research Operations Officer at ProofPilot, where she led the integration of AI-based tools to democratize clinical trial design and improve sponsor research execution. Savi has been recognized for building high-impact initiatives, from pioneering precision medicine programs and next-generation clinics at Mount Sinai to developing frameworks for data-driven healthcare innovation.
Amir Husain
Amir Husain is an entrepreneur, AI technologist, and author based in Austin, Texas. He is a recipient of Austin’s Top Entrepreneur award, UT Austin’s highest honor—the Presidential Citation—and has been inducted into UT Austin’s College of Natural Sciences Hall of Honor, as well as Austin’s 40 Under 40. Amir serves on the University of Texas at Austin’s President’s Advisory Board, the Advisory Board of the Department of Computer Science, and the Board of Global Venture Bridge.
Amir currently serves as Chairman of WorldQuant Foundry, Spec5, Argon, and Navigate. Amir founded SparkCognition (now Avathon), an industry-leading industrial AI company; SGS (now Avathon Government), a defense technology company chaired by former Deputy Secretary of Defense Robert Work; and SkyGrid, a joint venture created in partnership with Boeing.
Amir has been awarded over 30 patents in AI and distributed systems and has served on NATO’s Innovation Advisory Board.
Advisors
Munira Shabbir Moosajee
Dr. Munira Shabbir Moosajee is a Clinical Associate Professor and Head of Medical Oncology at Aga Khan University Hospital in Karachi, Pakistan. Board certified in Internal Medicine, Medical Oncology, and Hematology, she specializes in the management of lymphoma, leukemia, myeloma, breast, and gastrointestinal cancers. Dr. Moosajee is also the Director of the hospital’s Stem Cell Transplant Program and is widely recognized for her leadership in the field. She has received numerous accolades, including the Outstanding Teacher Award and AKU’s 10-Year Service Award. With international training from MD Anderson Cancer Center, her expertise extends to research, with multiple peer-reviewed publications focusing on improving clinical outcomes for cancer patients. Dr. Moosajee is committed to advancing oncology care and prioritizing compassionate, evidence-based treatment for her patients.
Nicholas Tatonetti
Dr. Nicholas Tatonetti is Professor and Vice Chair of Operations in the Department of Computational Biomedicine and Associate Director of Computational Oncology in the Cancer Center at Cedars-Sinai Medical Center. They received a PhD from Stanford University where they focused on the development of novel statistical and computational methods for observational data mining. Over the past 14 years, Dr. Tatonetti has applied these methods to drug safety surveillance and the discovery of dangerous adverse drug effects and has identified and validated previously unknown serious drug-drug interactions. Their lab at Cedars-Sinai is focused on using massive-scale real clinical and molecular data for making robust and validated scientific discoveries, with a particular focus on detecting, explaining, and validating drug effects and drug interactions. Dr. Tatonetti has published over 150 peer-reviewed scientific publications across medicine, systems biology, machine learning, and bioinformatics. Dr. Tatonetti is passionate about the integration of real-world data (such as those stored in the electronic health records) and high-dimensional biological data (captured using next-generation sequencing, high-throughput screening, and other "omics" technologies) to reimagine and rescale the scientific method.
WAITLIST
Access real-time trial options and support your patients’ next step in care.




